FYI - Based on very recent USA & China relations I just sold all my CASI shares. I just became very concerned with how China could negatively react to the USA Companies doing business in China. My concerns include CASI’s intellectual property for USA FDA approved drugs i.e. EVOMELA and relatively soon from ZEVALIN and (eventually) MARQIBO. For example, the China FDA approval is taking way too long for ZEVALIN - why? Is a ANDA (generic) in the making?
Market Data 
Markets 
AI
